|
1
|
Franco R, Zappavigna S, Gigantino V, Luce
A, Cantile M, Cerrone M, Facchini G, Perdonà S, Pignata S, Di
Lorenzo G, et al: Urotensin II receptor determines prognosis of
bladder cancer regulating cell motility/invasion. J Exp Clin Cancer
Res. 33:482014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fisher KE, Pop A, Koh W, Anthis NJ,
Saunders WB and Davis GE: Tumor cell invasion of collagen matrices
requires coordinate lipid agonist-induced G-protein and
membrane-type matrix metalloproteinase-1-dependent signaling. Mol
Cancer. 5:692006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stamenkovic I: Matrix metalloproteinases
in tumor invasion and metastasis. Semin Cancer Biol. 10:415–433.
2000. View Article : Google Scholar
|
|
6
|
Forget MA, Desrosiers RR and Béliveau R:
Physiological roles of matrix metalloproteinases: Implications for
tumor growth and metastasis. Can J Physiol Pharmacol. 77:465–480.
1999. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Curran S, Dundas SR, Buxton J, Leeman MF,
Ramsay R and Murray GI: Matrix metalloproteinase/tissue inhibitors
of matrix metalloproteinase phenotype identifies poor prognosis
colorectal cancers. Clin Cancer Res. 10:8229–8234. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gomez DE, Alonso DF, Yoshiji H and
Thorgeirsson UP: Tissue inhibitors of metalloproteinases:
Structure, regulation and biological functions. Eur J Cell Biol.
74:111–122. 1997.PubMed/NCBI
|
|
9
|
Mook OR, Frederiks WM and Van Noorden CJ:
The role of gelatinases in colorectal cancer progression and
metastasis. Biochim Biophys Acta. 1705:69–89. 2004.PubMed/NCBI
|
|
10
|
Koshiba T, Hosotani R, Wada M, Miyamoto Y,
Fujimoto K, Lee JU, Doi R, Arii S and Imamura M: Involvement of
matrix metalloproteinase-2 activity in invasion and metastasis of
pancreatic carcinoma. Cancer. 82:642–650. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo CB, Wang S, Deng C, Zhang DL, Wang FL
and Jin XQ: Relationship between matrix metalloproteinase 2 and
lung cancer progression. Mol Diagn Ther. 11:183–192. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papadopoulou S, Scorilas A, Arnogianaki N,
Papapanayiotou B, Tzimogiani A, Agnantis N and Talieri M:
Expression of gelatinase-A (MMP-2) in human colon cancer and normal
colon mucosa. Tumour Biol. 22:383–389. 2001. View Article : Google Scholar
|
|
13
|
Björklund M and Koivunen E:
Gelatinase-mediated migration and invasion of cancer cells. Biochim
Biophys Acta. 1755:37–69. 2005.PubMed/NCBI
|
|
14
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
García Z, Kumar A, Marqués M, Cortés I and
Carrera AC: Phosphoinositide 3-kinase controls early and late
events in mammalian cell division. EMBO J. 25:655–661. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Naujokat C, Fuchs D and Opelz G:
Salinomycin in cancer: A new mission for an old agent. Mol Med Rep.
3:555–559. 2010. View Article : Google Scholar
|
|
17
|
Jayapalan JJ, Ng KL, Razack AH and Hashim
OH: Identification of potential complementary serum biomarkers to
differentiate prostate cancer from benign prostatic hyperplasia
using gel- and lectin-based proteomics analyses. Electrophoresis.
33:1855–1862. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Herr MJ, Kotha J, Hagedorn N, Smith B and
Jennings LK: Tetraspanin CD9 promotes the invasive phenotype of
human fibrosarcoma cells via upregulation of matrix
metalloproteinase-9. PLoS One. 8:e677662013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: Biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
20
|
Chung TW, Moon SK, Lee YC, Kim JG, Ko JH
and Kim CH: Enhanced expression of matrix metalloproteinase-9 by
hepatitis B virus infection in liver cells. Arch Biochem Biophys.
408:147–154. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Basset P, Okada A, Chenard MP, Kannan R,
Stoll I, Anglard P, Bellocq JP and Rio MC: Matrix
metalloproteinases as stromal effectors of human carcinoma
progression: Therapeutic implications. Matrix Biol. 15:535–541.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamada KM, Kennedy DW, Yamada SS, Gralnick
H, Chen WT and Akiyama SK: Monoclonal antibody and synthetic
peptide inhibitors of human tumor cell migration. Cancer Res.
50:4485–4496. 1990.PubMed/NCBI
|
|
23
|
Watanabe H, Carmi P, Hogan V, Raz T,
Silletti S, Nabi IR and Raz A: Purification of human tumor cell
autocrine motility factor and molecular cloning of its receptor. J
Biol Chem. 266:13442–13448. 1991.PubMed/NCBI
|
|
24
|
Mukaida N, Gussella GL, Kasahara T, Ko Y,
Zachariae CO, Kawai T and Matsushima K: Molecular analysis of the
inhibition of interleukin-8 production by dexamethasone in a human
fibrosarcoma cell line. Immunology. 75:674–679. 1992.PubMed/NCBI
|
|
25
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim S, Ding W, Zhang L, Tian W and Chen S:
Clinical response to sunitinib as a multitargeted tyrosine-kinase
inhibitor (TKI) in solid cancers: A review of clinical trials. Onco
Targets Ther. 7:719–728. 2014.PubMed/NCBI
|
|
27
|
Antoszczak M, Popiel K, Stefańska J,
Wietrzyk J, Maj E, Janczak J, Michalska G, Brzezinski B and
Huczyński A: Synthesis, cytotoxicity and antibacterial activity of
new esters of polyether antibiotic - salinomycin. Eur J Med Chem.
76:435–444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ramsay AG, Marshall JF and Hart IR:
Integrin trafficking and its role in cancer metastasis. Cancer
Metastasis Rev. 26:567–578. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo BH, Carman CV and Springer TA:
Structural basis of integrin regulation and signaling. Annu Rev
Immunol. 25:619–647. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bellacosa A, Kumar CC, Di Cristofano A and
Testa JR: Activation of AKT kinases in cancer: Implications for
therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guo J, Jie W, Shen Z, Li M, Lan Y, Kong Y,
Guo S, Li T and Zheng S: SCF increases cardiac stem cell migration
through PI3K/AKT and MMP-2/-9 signaling. Int J Mol Med. 34:112–118.
2014.PubMed/NCBI
|
|
33
|
Hou J, Wang L, Jiang J, Zhou C, Guo T,
Zheng S and Wang T: Cardiac stem cells and their roles in
myocardial infarction. Stem Cell Rev. 9:326–338. 2013. View Article : Google Scholar
|
|
34
|
Theodosiou A and Ashworth A: MAP kinase
phosphatases. Genome Biol. 3:Reviews3009. 2002. View Article : Google Scholar : PubMed/NCBI
|
